Navigation Links
Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference

SAN FRANCISCO, November 15, 2011 /PRNewswire/ --

Pieris AG presented the results of the Company's first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein therapeutic, at the 2011 AACR-NCI-EORTC International Conference held in San Francisco, California.  The dose-escalation trial investigated the recommended Phase II dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 administered to patients with advanced solid tumors.  PRS-050 was well-tolerated, with no maximum tolerated dose reached, while demonstrating biological activity and a complete lack of immunogenicity, supporting further evaluation in a Phase II clinical trial.  

"The Phase I results not only confirm the safety and tolerability of PRS-050, but also are indicative of an attractive safety profile for Anticalins generally," said Dr. Laurent Audoly, Chief Scientific Officer for Pieris AG.  "Moreover, the results of our PK/PD strategy provide human data supporting the robustness of our drug platform.  The Anticalin approach, which in this case, plays on monovalent target engagement, small size and the lack of an effector function, is well-suited for a biobetter VEGF-targeted therapeutic protein approach to treat several types of cancer."

The Phase I clinical trial of PRS-050 was conducted in 26 patients with advanced solid tumors as an open-label, dose-escalating evaluation of the compound's safety, tolerability, and PK/PD profile.  The protein drug exhibited a half-life of six days, there was no immunogenicity (no anti-drug antibodies) observed across all cohorts and multiple dose-dependent PD effects were obtained.  PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) 40 kD PEGylated Anticalin discovered and developed internally at the company.  VEGF has a well-defined role in cancer angiogenesis, which is the mechanism by which cancer tumors increase blood vessel development at the tumor site and thereby enable further growth.  The compound began the clinical trial at three different sites in Germany during the first half of 2010.

The results were presented on Sunday, November 13th, 2011 at the American Association Cancer Researchers-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications is taking place November 12-16, 2011 at the Moscone Center West in San Francisco, California.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.  

About Pieris AG

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches.  Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris' pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development across a range of therapeutic areas.  The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.  Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit:

For further information, please contact:
Dr. Laurent Audoly, CSO
Pieris AG
Gretchen Schweitzer

Further information is available at  

Anticalin®, Anticalins® are registered trademarks of Pieris AG.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. China Medical Technologies Announces Payment on Maturity and Cancellation of its 3.5% Convertible Senior Subordinated Notes due November 15, 2011
4. Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering
5. MedClean Technologies Announces Third Quarter Results
6. Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC
7. Pregis Announces Third Quarter 2011 Financial Results
8. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
9. Dynatronics Announces First Quarter Results
10. Prometheus Announces New Chief Medical Officer
11. BioMed Realty Trust Announces Public Offering Price for 22,562,922 Shares of Common Stock
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a ... behalf of a home health care worker who provided companionship services for the elderly, ... workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... OH (PRWEB) , ... November 25, 2015 , ... Dental ... implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant ... this year in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... personal heating products business. Cozy Products explains what this means for business moving forward. ... with the Cozy Products business model: to sell personal heaters that reduce energy consumption, ...
Breaking Medicine News(10 mins):